Anxiety symptoms
Anxiolytic effects are Selank's primary clinical research theme.
Explore the research →ANXIETY & STRESS-RESPONSE RESEARCH
Selank
Selank is best known for interest around calm, anxiety, stress resilience and cognitive function, supported by early regional human research.
Anxiety researchStress responseCognition
Small regional clinical studies; broader confirmation neededComparative and clinical studies report anxiolytic signals, but the literature is relatively small, largely Russian-language and not equivalent to a large modern placebo-controlled programme.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why are people interested in Selank?
Selank is mainly talked about for feeling calmer while remaining mentally clear and functional. That combination — less anxiety or stress without feeling heavily sedated — is what gives it particular appeal around mood, focus and everyday resilience.
Cognition under stress
People are interested in calmness without sedation or reduced performance.
Explore the research →Stress resilience
Selank is discussed around acute stress, social anxiety and recovery from overload.
Explore the research →Immune-neural signalling
As a tuftsin analogue, Selank is also studied for immunomodulatory effects.
Explore the research →THE SCIENCE BIT
Exploring the brain's calming conversation.
Selank is based on tuftsin, a short immune-related peptide. Researchers study its influence on neural signalling and gene expression, including processes associated with GABA, an important inhibitory messenger.
That is a more careful explanation than calling it a direct GABA-receptor drug. A single confirmed target does not account for all its proposed effects, and the human evidence remains limited.
See the studies & trials →- Tuftsin-derived
- Peptide design
- GABA-related processes
- Inhibitory-signalling research
- Gene expression
- Experimental neural responses
How this connects to the research
Proposed mechanisms and early regional clinical research.
FROM MOLECULE TO TISSUE
Where Selank connects with the body
These are the tissues and biological systems behind the interest in Selank.
- Brain networks
- Anxiety and stress research.
- Neural cells
- Signalling experiments.
- Immune cells
- Related peptide biology.
The research behind the interest
Anxiety symptoms
Anxiolytic effects are Selank's primary clinical research theme.
Small studies comparing Selank with medazepam or phenazepam reported symptom improvements.
Early human evidenceExplore the studies →Cognition under stress
People are interested in calmness without sedation or reduced performance.
Clinical reports describe mild nootropic effects, but modern objective cognitive trials are limited.
Limited human evidenceExplore the studies →Stress resilience
Rather than simply causing sedation, much of the interest is about coping with stress while remaining mentally functional and alert.
Human symptom studies and preclinical stress models offer preliminary support.
Developing evidenceExplore the studies →Immune-neural signalling
As a tuftsin analogue, Selank is also studied for immunomodulatory effects.
Small studies report cytokine changes; clinical significance is uncertain.
Mechanistic + early human evidenceExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableSelank in generalized anxiety disorder and neurasthenia ↗
62 patients; Selank (30) compared with medazepam (32)
Intranasal Selank; oral comparator14 days
Anxiolytic effects were reported as similar between groups, with antiasthenic and psychostimulant effects also described for Selank.
The small Russian-language study and limited reporting prevent the confidence of a modern large placebo-controlled programme.
Selank compared with phenazepam in anxiety disorders ↗
60 patients with phobic-anxiety and somatoform disorders
Intranasal Selank; oral comparator
The report described anxiolytic and mild nootropic effects with a tolerability comparison.
It was not a large internationally replicated placebo-controlled programme.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceLimited
2/5 evidence depth
Several small clinical and comparative studies report anxiety-related effects.
✓
Clinical efficacyLimited
2/5 evidence depth
Lack of large blinded placebo-controlled replication limits efficacy certainty.
◇
Safety evidenceLimited
2/5 evidence depth
Short clinical courses provide some tolerability data; long-term and combination safety remain uncertain.
⌁
Preclinical evidenceDeveloping
3/5 evidence depth
Animal and molecular research supports anxiolytic and immune-neural mechanisms.
HOW TO READ THESE SCORESDeveloping preclinical evidence · limited human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
EVIDENCE LANDSCAPESelankMechanism → translation → human outcome
Small anxiety studies report a positive signal
Stress, neurotransmission and immune-neural research
Blinded replication, dose detail and long-term safety
What this snapshot does—and does not—show
It separates biological plausibility from demonstrated benefit. A compelling mechanism can justify better trials; it cannot substitute for them.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with Selank
Users explore Selank for anxiety reduction, social ease and calm focus. Small clinical reports make this more than a purely preclinical story, but evidence quality and replication remain limited.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Feeling calmer without feeling dulled
The appeal is less mental tension while staying able to work, talk and make decisions. People distinguish the desired calm from sedation, although experiences can be subtle or inconsistent.
- What makes a report informative
- Anxiety in familiar situations and the ability to function.
- What can muddy the picture
- Stress levels and expectations can fluctuate substantially without a compound effect.
Less friction in social situations
Interest includes overthinking conversations, anticipatory worry and feeling more at ease around other people. The practical outcome is participating more comfortably, not a guaranteed increase in sociability.
- What makes a report informative
- Comfort and participation in comparable social settings.
- What can muddy the picture
- Context, familiarity and other anxiety treatments affect the experience.
Calm focus during a busy day
Some people want quieter internal distraction rather than a stimulating boost. A useful account explains whether reduced tension actually helps concentration and task completion.
- What makes a report informative
- Concentration alongside alertness and day-to-day anxiety.
- What can muddy the picture
- Better sleep or lower workload can produce the same improvement.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Calmer without sedation
This is the most repeated positive theme in community discussion.
Human findings & limits
Comparative studies reported anxiolytic effects and reasonable tolerability, but were small.
Laboratory & animal context
Animal anxiety and neurotransmission studies support a non-benzodiazepine mechanism.
What this means: Encouraging early human signal requiring better controlled replication.
Social confidence and stress control
People often describe less anticipatory anxiety or improved social comfort.
Human findings & limits
Specific social-anxiety outcomes have not been established in large trials.
Laboratory & animal context
Stress-response research provides a plausible basis.
What this means: Community detail is more specific than the published evidence.
Calm focus
Selank is commonly paired with cognitive-performance goals.
Human findings & limits
Mild nootropic effects were reported in small studies; objective evidence remains limited.
Laboratory & animal context
Memory and neurotrophic mechanisms are explored in animal work.
What this means: Potentially interesting, but not a proven cognitive enhancer.
Short intranasal courses
Community descriptions often mirror the brief course structure seen in regional clinical literature, but use different concentrations and spray devices.
Human findings & limits
Small studies support intranasal exposure over short treatment windows; their abstracts do not provide enough product-delivery detail to validate a retail spray conversion.
Laboratory & animal context
Animal dose and route research cannot establish the amount delivered by a human nasal product.
What this means: A recognisable route and course pattern, with major dose-accuracy and replication gaps.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
ONE ANECDOTAL COMMUNITY EXAMPLE
ANECDOTAL · UNVALIDATEDA brief intranasal course with a review point
The route and short-course idea resemble regional clinical research, but the amount below is community-described and product delivery varies.
1Days 1–3
250 mcg / dayAnecdotal intranasal starting amount
2Days 4–7
250–500 mcg / daySome descriptions divide daily use
3Days 8–14
Up to 750 mcg / dayUpper end of recurring community descriptions
4After course
Pause & reviewNo validated maintenance interval
What people commonly discuss250–750 mcg/day intranasally for 10–14 days, with divided use appearing in some descriptions.
What remains unvalidatedThe commonly shared amount, spray conversion, escalation and break pattern have not been validated in a modern dose-finding trial.
ROUTE & DELIVERYConcentration and pump volume decide delivery
Two products can deliver very different micrograms per spray. Study route does not validate an unlabelled or inaccurately compounded nasal product.
PROFESSIONAL SOURCE CONTEXT
Selank GAD comparative study · PubMed ↗The source shows what has actually been studied. It does not validate the community example above or turn it into guidance.
Clinical publications describe short intranasal courses, but no internationally validated Selank protocol exists for general anxiety or wellness use.
No structured human dosing protocol has been added for this compound. That should not be interpreted as evidence for a community dosing schedule.
COMMUNITY DISCUSSION
Anecdotal / unvalidated · regional clinical extrapolationWhat people commonly discuss
STARTING APPROACHES
Community descriptions often begin around 250 mcg intranasally per day; 500–750 mcg/day in divided use is also discussed.
DURATION / CYCLES
Short 10–14-day courses are common, while some people describe occasional use around stressful periods.
MAINTENANCE DISCUSSION
No validated continuous-use, cycling, tolerance-prevention or break schedule exists.
Community patterns are anecdotal and unvalidated unless a linked human study independently supports the same approach.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Intranasal formulation guide
Regional human evidence · limited generalisationRegional anxiety studies and community nasal descriptions use different formulations and exposures. Enter a verified delivered amount and your recorded times. Vial contents do not determine the amount in one spray.
Form and route: Intranasal; product-specific concentration and delivery
The planner keeps amounts and repeat patterns blank for this compound. Use its formulation guide to record an independently specified schedule.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Often combined with
OFTEN COMBINED WITH
Community rationale · component roles · evidence boundaryWhy people explore pairings with Selank
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
Potential first, evidence in context. Pairings are usually explored because their research stories appear complementary. That makes them interesting to study, but does not yet prove extra benefit or safety.
CURRENT COMPOUNDSelank
→
OFTEN EXPLORED WITHSelank + Semax
Selank + Semax
→
OFTEN EXPLORED WITHSelank + psychological therapy
Selank + Evidence-based therapy
Combination-specific human research is the strongest evidence for what a pairing adds. Evidence for either ingredient alone should not be silently transferred to the combination.
SSELANK IS USUALLY DISCUSSED AROUNDAnxiety, stress response and calm cognition
＋Small human studies motivate interest, while modern placebo-controlled replication remains the central gap.
PTHE PAIRED APPROACH MAY ADDGreater activation or evidence-based psychological treatment
Semax adds a more activating research story; therapy adds an established behavioural approach, not a proven peptide synergy.
＋
OFTEN EXPLORED WITH
Explore →＋Selank + Semax
Selank + SemaxWHY IT IS EXPLOREDExplored around calm focus and stress-resilient cognition.
No controlled human evidence for the combination.OFTEN EXPLORED WITH
Explore →Selank + psychological therapy
Selank + Evidence-based therapyWHY IT IS EXPLOREDCommunities discuss combining symptom relief with behavioural treatment.
Selank has not been shown to enhance therapy outcomes and should not replace established care.01Keep the goal measurable
Anxiety relief, social comfort and productivity require different outcomes and follow-up.
02Protect established care
A peptide pairing should not trigger abrupt changes to prescribed psychiatric treatment.
03Watch the combined state
Sleep loss, agitation or mood change may matter more than the rationale for a stack.
Safety context
SAFETY & UNCERTAINTY
Short-term tolerability is better studied than long-term use
01ENCOURAGING CONTEXTSmall human anxiety studies exist
Short comparative courses provide a preliminary tolerability and efficacy signal beyond preclinical work alone.
02THE IMPORTANT BOUNDARYSmall comparisons are not definitive treatment evidence
Limited blinding, regional reporting and absent large replication leave the size and reliability of benefit uncertain.
03WHAT REMAINS UNKNOWNLong-term use and psychiatric-medication interactions
Repeated courses, dependency expectations, mood effects and combination safety have not been established.
What the current evidence saysSmall clinical studies provide some reassurance for short courses, but long-term neuropsychiatric effects, interactions, product concentration and combined use with psychiatric medicines are not well characterised.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Stopping prescribed anxiety treatment can cause harm; changes should be discussed with the treating clinician.
A spray count without delivered micrograms is not a reproducible dose.
Severe agitation, suicidal thinking, panic escalation or marked mood change requires urgent professional support.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
4 sourcesSources used on this profile
CURRENT STATUS
How to interpret its position today
No UK-authorised medicine is represented on this profile
Selank is presented as a research compound. The MHRA products database should be checked for any future change in authorised status.
MHRA products database ↗No FDA-approved therapeutic product identified
Regulatory evaluation of a substance for compounding is separate from approval of a drug for safety and efficacy.
FDA Drugs@FDA database ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.